Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simris Alg ABFRA:5LU -15.15%19 EBIT per Share is €-0.00 as of Mar. 2026. GuruFocus rates FRA:5LU with a GF Score™ of 19/100. The stock has 6 warning signs investors should review. Among 1,173 Biotechnology companies, Simris Alg AB ranks better than 75.02% on this metric.
Simris Alg AB's EBIT per Share for the
three
months ended in Mar. 2026 was €0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 35.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 24.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 26.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Simris Alg AB's EBIT per Share or its related term are showing as below:
FRA:5LU'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -38.6 Med: 25.6 Max: 43
Current: 35.2
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Simris Alg AB was 43.00% per year. The lowest was -38.60% per year. And the median was 25.60% per year.
FRA:5LU's 3-Year EBIT Growth Rate is ranked better than 75.02% of 1173
companies
in the Biotechnology industry
Industry Median: 15.5
vs FRA:5LU: 35.20
Simris Alg AB's EBIT for the
three
months ended in Mar. 2026 was €-0.52 Mil.
Simris Alg AB (FRA:5LU) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Simris Alg AB EBIT per Share Related Terms
Simris Alg AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Simris Alg AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simris Alg AB (FRA:5LU) has a EBIT per Share of €-0.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Simris Alg AB and its competitors. According to the industry distribution chart, Simris Alg AB ranks #293 out of 1173 companies in the Biotechnology industry, placing it in the top 25%.
Is Simris Alg AB's EBIT per Share too high?
Simris Alg AB's current EBIT per Share is €-0.00. Based on the distribution chart, Simris Alg AB ranks #293 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Simris Alg AB has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Simris Alg AB's EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Simris Alg AB ranks #293 out of 1173 companies for EBIT per Share. This places Simris Alg AB in the top 25% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Simris Alg AB and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simris Alg AB's current EBIT per Share is €-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simris Alg AB stock overvalued right now?
Simris Alg AB (FRA:5LU) has a current EBIT per Share of €-0.00. The current EBIT per Share is €-0.00. Simris Alg AB's overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Simris Alg AB (FRA:5LU), the current EBIT per Share is €-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.
19GF Score
Get the complete analysis for FRA:5LU
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5LU has been successfully added to your 
